Prognostic Factors in Locoregional Non-Small Cell Lung Cancer Treated with Radiotherapy

Coen, V.; Lancker, M. Van; Neve, W. De; Storme, Guy

doi:10.1097/00000421-199504000-00004

Cited by 18 publications

(16 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, patients with and without atelectasis were similar in terms of stage of the disease, mediastinal lymph node status, distant metastasis tumor size and histology (table 3). In contrast to our findings, Coen et al [7 ]reported that survival was not influenced by the presence of total or partial atelectasis. Although our results need further confirmation, the prolonged survival rates in our study may be related to a possible decrease of intratumoral blood flow because of vascular shunts in the neighboring atelectatic lung segment [16].…”

Section: Discussioncontrasting

confidence: 99%

“…The rapidly growing body of literature has identified more than 150 prognostic factors pertaining to the tumor, patient or environment [3,4,5,6,7,8,9,10,11,12,13]. Stage of the disease, mediastinal lymph node involvement, performance status of the patient, hypercalcemia and weight loss are well-known prognostic factors in lung cancer patients [3, 4].…”

Section: Discussionmentioning

confidence: 99%

“…During the first presentation and follow-up period, a significant proportion of patients experience some thoracic changes including atelectasis, pleural effusion, vena cava superior syndrome (VCSS), recurrent laryngeal nerve involvement (LNI) and obstructive pneumonitis [1, 2]. Among many clinical, pathologic and molecular prognostic factors, some tumor-related secondary intrathoracic changes including pleural effusion, VCSS and LNI have also been analyzed in several studies [3,4,5,6,7,8,9,10,11,12,13]. However, some other changes, especially atelectasis and obstructive pneumonitis, have not been evaluated clearly.…”

Section: Introductionmentioning

confidence: 99%

“…Furthermore, the role of each intrathoracic change was analyzed separately, and no study reported a cumulative effect of all those changes on survival. The relationship between atelectasis and survival was only reported in a single study by Coen et al [7], who showed that survival was not influenced by the presence of partial or total atelectasis. There are also some controversies between some reports [8, 9].…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Survival Analyses of Patients with Thoracic Complications Secondary to Bronchial Carcinoma at the Time of Diagnosis

Bülbül

Öztuna²,

Topba³

et al. 2005

Respiration

View full text Add to dashboard Cite

Background: The impact on survival of thoracic complications secondary to bronchial carcinoma has not been clearly analyzed. Objectives: The purpose of this study was to assess the significance of these complications for the survival of lung cancer patients. Methods: All patients diagnosed at our center from March 2000 to January 2004 were analyzed to estimate survival among patients with or without thoracic complication. Any intrathoracic change or abnormality secondary to bronchial carcinoma such as atelectasis or pleural effusion was defined a thoracic complication. Survival was calculated using the Kaplan-Meier method, and the complications predicting survival were evaluated using Cox’s regression analysis. Results: Of the 182 eligible patients, 61.5% had at least one thoracic complication. The complications were atelectasis, pulmonary metastases, pleural effusion, laryngeal nerve involvement, vena cava superior syndrome and others. Specific survival times for each complication were not different, except in the case of atelectasis. Median survival was significantly longer in patients with atelectasis, as opposed to nonatelectatic patients. Survival times in patients with at least one complication were not different than those of patients without complication. However, median survival of patients with one of the complications, excluding atelectasis (since this was associated with improved survival), was 3 months shorter (p = 0.029). Cox’s regression analysis also predicted atelectasis for improved survival. Conclusion: Atelectasis, which was determined to be the most frequent thoracic complication, was identified as a favorable prognostic factor in patients with advanced stage lung cancer.

show abstract

Section: Discussioncontrasting

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Survival Analyses of Patients with Thoracic Complications Secondary to Bronchial Carcinoma at the Time of Diagnosis

Bülbül

Öztuna²,

Topba³

et al. 2005

Respiration

View full text Add to dashboard Cite

show abstract

“…However, in early stages, its independent predictive value has not been validated by several reports [2,3]. Moreover, its significance in advanced stages is not well established, due to the paucity of the published literature on this issue [4,5]. Based on our clinical experience, we observed that the presence of At does not prefigure a worse outcome.…”

Section: Introductionmentioning

confidence: 65%

The favorable prognostic significance of atelectasis in patients with advanced non-small cell lung cancer: Results of a prospective observational study

et al. 2009

View full text Add to dashboard Cite

A practical prognostic index for inoperable non-small-cell lung cancer

Wigren

Oksanen

Kellokumpu‐Lehtinen

1997

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

Radical radiotherapy is widely used to treat inoperable non-small-cell lung cancer (NSCLC) although only a small number of patients benefit in the long run from this intensive treatment. There is a small proportion of long-term survivors who might derive advantage from even more aggressive radiotherapy combined with chemotherapy. In order to support optimal treatment selection we have carried out univariate and multivariate analyses of possible prognostic variables in the retrospective data of 502 NSCLC patients treated at one institute with external radiotherapy, both with curative and palliative intent. To obtain more accurate tools for a rational treatment decision, we identified, by using Cox's proportional-hazards model, the five most powerful determinants of overall survival and combined them to a prognostic index. On the basis of only the number of these risk factors (advanced stage, general or metastatic symptoms, poor performance status, anemia and tumor size of at least 7 cm), the patient falls into one of the six possible prognostic groups and these groups turned out to be identifiable as separate prognostic clusters. Thirty-one per cent of the patients have three or more risk factors and a median survival of 5-7 months compared with 18 months for patients without any non-favorable factor. Furthermore, the prognostic factors were so strong that multivariate analyses did not reveal the treatment selection to have any significant influence on survival. As each of the five variables have the advantage of being routinely available, our index is simple enough to be used in daily clinical practice. The clinical value of the prognostic index should be verified by using independent data.

show abstract

Prognostic Factors in Locoregional Non-Small Cell Lung Cancer Treated with Radiotherapy

Cited by 18 publications

References 0 publications

Survival Analyses of Patients with Thoracic Complications Secondary to Bronchial Carcinoma at the Time of Diagnosis

Survival Analyses of Patients with Thoracic Complications Secondary to Bronchial Carcinoma at the Time of Diagnosis

The favorable prognostic significance of atelectasis in patients with advanced non-small cell lung cancer: Results of a prospective observational study

A practical prognostic index for inoperable non-small-cell lung cancer

Contact Info

Product

Resources

About